146 related articles for article (PubMed ID: 38294346)
1. Food-Drug Effects and Pediatric Drug Development Studies Submitted to the US Food and Drug Administration, 2012-2022.
Tunehag KR; George B; Samuels S; Vo K; Arya V; Abulwerdi G; Burckart GJ
J Clin Pharmacol; 2024 Jun; 64(6):697-703. PubMed ID: 38294346
[TBL] [Abstract][Full Text] [Related]
2. Adolescent dosing and labeling since the Food and Drug Administration Amendments Act of 2007.
Momper JD; Mulugeta Y; Green DJ; Karesh A; Krudys KM; Sachs HC; Yao LP; Burckart GJ
JAMA Pediatr; 2013 Oct; 167(10):926-32. PubMed ID: 23921678
[TBL] [Abstract][Full Text] [Related]
3. Improving pediatric dosing through pediatric initiatives: what we have learned.
Rodriguez W; Selen A; Avant D; Chaurasia C; Crescenzi T; Gieser G; Di Giacinto J; Huang SM; Lee P; Mathis L; Murphy D; Murphy S; Roberts R; Sachs HC; Suarez S; Tandon V; Uppoor RS
Pediatrics; 2008 Mar; 121(3):530-9. PubMed ID: 18310202
[TBL] [Abstract][Full Text] [Related]
4. Completion Rate and Reporting of Mandatory Pediatric Postmarketing Studies Under the US Pediatric Research Equity Act.
Hwang TJ; Orenstein L; Kesselheim AS; Bourgeois FT
JAMA Pediatr; 2019 Jan; 173(1):68-74. PubMed ID: 30452498
[TBL] [Abstract][Full Text] [Related]
5. Combined Pediatric and Adult Trials Submitted to the US Food and Drug Administration 2012-2018.
Tanaudommongkon I; John Miyagi S; Green DJ; Burnham JM; van den Anker JN; Park K; Wu J; McCune SK; Yao L; Burckart GJ
Clin Pharmacol Ther; 2020 Nov; 108(5):1018-1025. PubMed ID: 32394430
[TBL] [Abstract][Full Text] [Related]
6. Obesity Considerations in Pediatric Drug Development, 2016-2021.
Samuels S; Bhatt-Mehta V; Park K; Burckart GJ
J Clin Pharmacol; 2023 Nov; 63 Suppl 2():S18-S24. PubMed ID: 37942908
[TBL] [Abstract][Full Text] [Related]
7. Pediatric Efficacy Extrapolation in Drug Development Submitted to the US Food and Drug Administration 2015-2020.
Samuels S; Park K; Bhatt-Mehta V; Sun H; Mulugeta Y; Yao L; Green DJ; Burckart GJ
J Clin Pharmacol; 2023 Mar; 63(3):307-313. PubMed ID: 36150423
[TBL] [Abstract][Full Text] [Related]
8. Exposure-Response Assessment in Pediatric Drug Development Studies Submitted to the US Food and Drug Administration.
Zhang Y; Wang Y; Khurana M; Sachs HC; Zhu H; Burckart GJ; Alexander J; Yao LP; Wang J
Clin Pharmacol Ther; 2020 Jul; 108(1):90-98. PubMed ID: 32030741
[TBL] [Abstract][Full Text] [Related]
9. Inconsistent labeling of food effect for oral agents across therapeutic areas: differences between oncology and non-oncology products.
Kang SP; Ratain MJ
Clin Cancer Res; 2010 Sep; 16(17):4446-51. PubMed ID: 20736327
[TBL] [Abstract][Full Text] [Related]
10. Extrapolation of adult data and other data in pediatric drug-development programs.
Dunne J; Rodriguez WJ; Murphy MD; Beasley BN; Burckart GJ; Filie JD; Lewis LL; Sachs HC; Sheridan PH; Starke P; Yao LP
Pediatrics; 2011 Nov; 128(5):e1242-9. PubMed ID: 22025597
[TBL] [Abstract][Full Text] [Related]
11. Obesity and Pediatric Drug Development.
Vaughns JD; Conklin LS; Long Y; Zheng P; Faruque F; Green DJ; van den Anker JN; Burckart GJ
J Clin Pharmacol; 2018 May; 58(5):650-661. PubMed ID: 29350758
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal Antibodies and Fc-Fusion Proteins for Pediatric Use: Dosing, Immunogenicity, and Modeling and Simulation in Data Submitted to the US Food and Drug Administration.
Liu XI; Dallmann A; Wang YM; Green DJ; Burnham JM; Chiang B; Wu P; Sheng M; Lu K; van den Anker JN; Burckart GJ
J Clin Pharmacol; 2019 Aug; 59(8):1130-1143. PubMed ID: 30865317
[TBL] [Abstract][Full Text] [Related]
13. Pediatric Drug Development: Outlook for Science-Based Innovation.
Green DJ; Zineh I; Burckart GJ
Clin Pharmacol Ther; 2018 Mar; 103(3):376-378. PubMed ID: 29384202
[TBL] [Abstract][Full Text] [Related]
14. Effects of the pharmaceutical technologic aspects of oral pediatric drugs on patient-related outcomes: a systematic literature review.
van Riet-Nales DA; Schobben AF; Egberts TC; Rademaker CM
Clin Ther; 2010 May; 32(5):924-38. PubMed ID: 20685501
[TBL] [Abstract][Full Text] [Related]
15. Oral biopharmaceutics tools: recent progress from partnership through the Pharmaceutical Education and Research with Regulatory Links collaboration.
O'Dwyer PJ; Box KJ; Dressman J; Griffin BT; Henze LJ; Litou C; Pentafragka C; Statelova M; Vertzoni M; Reppas C
J Pharm Pharmacol; 2021 Mar; 73(4):437-446. PubMed ID: 33793836
[TBL] [Abstract][Full Text] [Related]
16. IOM Review of FDA--approved biologics labeled or studied for pediatric use.
Field MJ; Ellinger LK; Boat TF
Pediatrics; 2013 Feb; 131(2):328-35. PubMed ID: 23319521
[TBL] [Abstract][Full Text] [Related]
17. Exposure Matching of Pediatric Anti-infective Drugs: Review of Drugs Submitted to the Food and Drug Administration for Pediatric Approval.
Zimmerman K; Putera M; Hornik CP; Brian Smith P; Benjamin DK; Mulugeta Y; Burckart GJ; Cohen-Wolkowiez M; Gonzalez D
Clin Ther; 2016 Sep; 38(9):1995-2005. PubMed ID: 27364807
[TBL] [Abstract][Full Text] [Related]
18. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
19. Role of Quantitative Clinical Pharmacology in Pediatric Approval and Labeling.
Mehrotra N; Bhattaram A; Earp JC; Florian J; Krudys K; Lee JE; Lee JY; Liu J; Mulugeta Y; Yu J; Zhao P; Sinha V
Drug Metab Dispos; 2016 Jul; 44(7):924-33. PubMed ID: 27079249
[TBL] [Abstract][Full Text] [Related]
20. Esomeprazole FDA Approval in Children With GERD: Exposure-Matching and Exposure-Response.
Earp JC; Mehrotra N; Peters KE; Fiorentino RP; Griebel D; Lee SC; Mulberg A; Röhss K; Sandström M; Taylor A; Tornøe CW; Wynn EL; Van der Walt JS; Garnett C
J Pediatr Gastroenterol Nutr; 2017 Sep; 65(3):272-277. PubMed ID: 27875488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
